OTC Markets Group uses cookies and similar technologies to help us understand how you use our websites, as further disclosed in our Privacy Policy. Our Terms of Service contain important information including restrictions on your use of our websites. By clicking “Accept”, or by continuing to use our websites, you consent to the use of cookies and agree to the terms of the OTC Markets Group Privacy Policy and Terms of Service.
PVCT
Provectus Biopharmaceuticals, Inc.
0.0731
0.002
2.81%
0.0721 / 0.0731 (180000 x 10000)
Provectus Biopharmaceuticals, Inc.
800 S. Gay Street
Suite 1610
Knoxville, TN 37929
800 S Gay Street
Suite 1610
Knoxville, TN 37929
John W. "Jack" Lacey, III, MD
500 West Monroe St, Suite 2000
Chicago, IL 60661
400 - 22 East 5th Avenue
Vancouver, BC V5T 1G8
Canada
211 Commerce Street
Suite 800
Nashville, TN 37201
Provectus Biopharmaceuticals, Inc., a Delaware corporation, is a clinical-stage biotechnology company developing immunotherapy medicines for different diseases that are based on a class of synthetic small molecule immuno-catalysts called halogenated xanthenes. Our lead molecule is named rose bengal sodium.
The Company currently leases 2,700 square feet of corporate office space in Knoxville, Tennessee through an operating lease agreement for a term of five years ending on June 30, 2027. The office space is used by both R&D and G&A to operate the day-to-day business.
